摘要
目的观察小金丸联合尼美舒利治疗亚急性甲状腺炎（SAT）的临床疗效。方法70例SAT患者随机分为2组。尼美舒利组35例，给予尼关舒利0．1g，2次／d，口服。联合治疗组35例，给予小金丸1．2g，2次／d，口服；尼美舒利0．1g，2次／d，口服。2组连续用药3～4周，病情缓解后将用药剂量减半维持治疗8周。观察治疗后的疗效和停药后12周的复发率以及药物不良反应。结果尼美舒利组与联合治疗组的治疗有效率分别为82．9％（29／35）和85．7％（30／35），体温高于39℃者2组的治疗有效率均为50．0％（3／6），尼关舒利组与联合治疗组退热时间差异无统计学意义（P〉0．05），但联合治疗组对于甲状腺疼痛、压痛消退时间、第1周红细胞沉降率下降正常率、第3周甲状腺肿大或结节的回缩正常率以及停药后12周复发率，均明显优于尼美舒利组（P均〈0．05）。2组均无严重不良事件发生。结论对于非高热SAT患者，选择小金丸联合尼美舒利治疗可以发挥协同治疗效应，是安全有效的治疗方案之一。
Objective To assess the effect of xiaojin wan plus nimesulide on patients with subacute granulomatous thyroiditis（SAT）. Methods 70 SAT cases were divided into nimesulide group （nimesulide 0. 1 g, 2/d） and combined group（ nimesulide 0. 1 g,2/d and xiaojin wan 1.2 g,2/ d）. When the patients＇ conditions were relieved after 3-4 weeks treatment,half doses of the medicines were given in two groups for 8 weeks. The efficacy, safety and relapse rate after withdrawing medicines for 12 weeks were observed. Results The effective rates were 82.9% （29/35） in nimesulide group and 85.7% （30/35）in combined group, but both groups＇ effective rate was 50.0% （3/6） in patients with high temperature （ higher than 39 ℃ ）. The time for fever relieved in two groups were similar （P 〉 0.05）, but the thyroid pain smoothing time, normalized rates of blood sedimentation after 1 week therapy, enlarged thyroid or thyroid nodule after 3 week therapy, relapsed rate were significantly more efficacious in combined group than in nimesulide group （P 〈 0.05）. There was no severe side effects in the two groups. Conclusions There is a synergic effect of xiaojin wan plus nimesulide on patients with SAT, that is an effective and safe therapeutic regimen for SAT patients without high temperature.
出处
《中国综合临床》
2009年第11期1166-1168,共3页
Clinical Medicine of China
关键词
亚急性甲状腺炎
中药
非甾体类消炎镇痛药
Subacute granulomatous thyroiditis
Chinese medicine
Nonsteriod anti-inflamatory drugs
